Dazodalibep

Summary

Dazodalibep (CHEMBL4594331) is a phase-3 clinical-stage protein; indicated across 5 conditions including sjogren syndrome and rheumatoid arthritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 5 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594331
Name	Dazodalibep
Type	Protein
Max phase	3

Also known as: Dazodalibep, Medi 4920, MEDI-4920, MEDI4920, VIB-4920, Vib4920, VIB4920, DAZODALIBEP

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Sjogren syndrome	3	MONDO:0010030	EFO:0000699
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
lupus nephritis	2	MONDO:0005556	EFO:0005761
autoimmune disease	1	MONDO:0007179	EFO:0005809
autoimmune thrombocytopenic purpura	1	MONDO:0008558	EFO:0007160

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06104124	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06245408	PHASE3	ACTIVE_NOT_RECRUITING	A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren’s Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06747949	PHASE3	RECRUITING	A Long-term Extension Study of Dazodalibep in Participants With Sjögren’s Syndrome (SS)
NCT05201469	PHASE2	RECRUITING	VIBRANT: VIB4920 for Active Lupus Nephritis
NCT04046549	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
NCT04129164	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren’s Syndrome
NCT04163991	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
NCT04174677	PHASE2	WITHDRAWN	Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
NCT02151110	PHASE1	COMPLETED	Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
NCT02780388	PHASE1	COMPLETED	A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).